Kronalis

Tadalafil, the active ingredient in Kronalis, is a phosphodiesterase type 5 (PDE5) inhibitor presented as an oral tablet for oral use. It treats erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension in adult patients.

GNH USA supplies Kronalis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent quality for global healthcare markets.

Tadalafil acts on the phosphodiesterase‑5 pathway to improve smooth muscle relaxation in several target organs.

- Erectile dysfunction: improves ability to achieve and maintain an erection in men with this condition. - Benign prostatic hyperplasia: reduces urinary symptoms by relaxing prostate and bladder‑neck smooth muscle. - Pulmonary arterial hypertension: lowers pulmonary arterial pressure and improves exercise capacity in affected patients.

Tadalafil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Flushing - Indigestion - Nasal congestion - Back pain

Serious or Rare Side Effects: - Vision loss - Priapism (prolonged erection) - Sudden hearing loss - Severe hypotension - Allergic reactions such as rash or anaphylaxis

Before prescribing Kronalis, clinicians should evaluate patient history and follow safety measures.

- Cardiovascular assessment: review heart disease, recent myocardial infarction, and uncontrolled hypertension. - Concomitant nitrate therapy: avoid use with nitrates due to risk of severe hypotension. - Alpha‑blocker use: use with caution and monitor blood pressure. - CYP3A4 inhibitor use: adjust dose or monitor for increased exposure. - Store below 25°C: keep in the original packaging, protect from moisture.

Tadalafil interacts with several medicines; some combinations must be avoided while others require monitoring.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin, isosorbide dinitrate). - Guanylate cyclase stimulators (e.g., riociguat). - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin). - Alpha‑blockers (e.g., prazosin) in patients at risk of hypotension.

Moderate Interactions (Monitor Closely): - Antihypertensives (e.g., beta‑blockers, calcium channel blockers). - Other PDE5 inhibitors (combined use may increase adverse effects). - CYP3A4 inducers (e.g., rifampin, carbamazepine). - Alcohol and grapefruit juice, which can modify plasma levels.